ArticleJournal of the Society for Cardiovascular Angiography & Interventions2025
First-in-human TAVR With Navitor Self-expanding Intra-annular Valve in LVAD-Associated Aortic Regurgitation.
Article in Journal of the Society for Cardiovascular Angiography & Interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Self-Expanding Supra-Annular Transcatheter Valve for Pure Native Aortic Insufficiency: Rationale and Technique.JACC. Case reports · 2026Article
- Interplay between medical and interventional therapies in valvular heart disease and heart failure: an expert opinion paper.ESC heart failure · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aortic regurgitation (AR) is commonly reported in patients with left ventricular assist device (LVAD) and is associated with poor outcomes. Surgical management of AR in these patients carries high operative mortality. Dedicated transcatheter options for AR are limited to research trials and are not commercially available. Transcatheter aortic valve replacement (TAVR) in patients with LVAD and AR is challenging due to a lack of adequate annular calcium to anchor the valve with a high risk of embolization. Methods: Two patients with severe LVAD-associated AR and heart failure were referred for consideration for TAVR. Evaluation of the aortic valve revealed no significant valve calcification. They were attempted to be enrolled in trials of the JenaValve and J-valve but failed screening due to the presence of LVAD. Compassionate use of these AR-dedicated TAVR valves was closed due to registries that are going to begin later in 2025. Hence, after heart team approach, we proceeded with commercially available Navitor self-expanding intra-annular valve (Abbott) that has the largest aortic diameter. Results: We were able to successfully treat AR due to LVAD using the Navitor valve without valve migration at the recommended depth. Conclusions: Commercial TAVR devices for LVAD-associated AR carry high risk of embolization in the absence of valve calcification. Abbott Navitor valve with its unique frame design can be used safely to treat AR associated with LVAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.